Rani Therapeutics
RANI
38 hedge funds and large institutions have $4.58M invested in Rani Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
4% more call options, than puts
Call options by funds: $147K | Put options by funds: $142K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.63% less ownership
Funds ownership: 11.47% → 10.84% (-0.63%)
10% less funds holding
Funds holding: 42 → 38 (-4)
13% less capital invested
Capital invested by funds: $5.23M → $4.58M (-$656K)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 2 |
CAMG
CWA Asset Management Group
Naples,
Florida
|
+$123K |
| 3 |
FWP
Forefront Wealth Partners
Austin,
Texas
|
+$96.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$71.9K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$399K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$176K |
| 3 |
Two Sigma Advisers
New York
|
-$151K |
| 4 |
VF
Virtu Financial
New York
|
-$62K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$40.7K |
RANI Hedge Fund Activity: Q1 2025 in Review
38 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q1 2025, worth a combined $4.58M — down 13% from $5.23M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RANI and 6 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $133K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $399K sold.
- 38 institutional investors held Rani Therapeutics (RANI) as of Q1 2025, down from 42 in Q4 2024.
- Funds reported $4.58M of Rani Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
- 6 funds opened new Rani Therapeutics positions in Q1 2025 and 9 closed out, a net change of -3 holders.
- The largest Rani Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $133K added.
- The largest Rani Therapeutics seller in Q1 2025 was Two Sigma Investments, an estimated $399K sold.
Based on aggregated 13F filings for Q1 2025.